KEY DETAILS
A randomized trial published Oct 1, 2026 in Nature Medicine reported that mechanisms of kidney protection by semaglutide may include vascular and molecular changes in type 2 diabetes.
A randomized, double-blind, placebo-controlled trial published Sept 29, 2026 in Nature Medicine supports once-daily oral safiglipron as an effective treatment option for type 2 diabetes.
A meta-analysis published Sept 29, 2026 reported that dual GLP-1/glucagon receptor agonists produce meaningful weight loss and metabolic improvements with acceptable short-term safety.
A separate Sept 29, 2026 systematic review and network meta-analysis found that SGLT2 inhibitors plus metformin and GLP-1 receptor agonist or dual incretin agonist therapy are both reasonable initial glucose-lowering strategies.
The FTC's lawsuit against Hims & Hers Health, Inc. is pending in the Northern District of California, with its latest recorded action on July 29, 2026.
A randomized trial published Oct 1, 2026 adds to what researchers understand about semaglutide and kidney health in type 2 diabetes. It sits alongside several other diabetes and obesity studies published on Sept 29, 2026. The FTC's case against Hims & Hers Health is also pending, with its latest recorded action on July 29, 2026.
This one digs into the how, not just the what. A randomized, placebo controlled trial published October 1, 2026, in Nature Medicine looked at semaglutide's effects on kidney disease in people with type 2 diabetes. The results indicate that the mechanisms behind that kidney protection may include reduced vascular resistance, prevention of fibrosis, and improved molecular programs that promote endothelial cell health.
Oral drugs in this class keep drawing attention. A randomized, double-blind, placebo-controlled trial published September 29, 2026, in Nature Medicine tested oral safiglipron in people with early type 2 diabetes. The findings support once-daily oral safiglipron as an effective treatment option for type 2 diabetes.
Weight loss drugs are evolving beyond single-hormone targets. A meta-analysis published on September 29, 2026, in Diabetes, Obesity and Metabolism reported that dual GLP-1/glucagon receptor agonists produce meaningful weight loss and metabolic improvements with acceptable short-term safety. Longer head-to-head trials are needed to confirm durability and cardiovascular safety, the analysis noted.
Choosing a first diabetes treatment is rarely a one-size-fits-all decision. A September 29, 2026, systematic review and Bayesian network meta-analysis in Diabetes, Obesity and Metabolism found that SGLT2 inhibitors plus metformin and GLP-1 receptor agonist or dual incretin agonist therapy are both reasonable contemporary initial glucose-lowering strategies for type 2 diabetes. The analysis said selection between these strategies should take into consideration phenotype, treatment priorities, tolerability, cost, access and patient preference.
The FTC's lawsuit against Hims & Hers Health, Inc. is pending in the District Court for the Northern District of California. The latest recorded action in the case was on July 29, 2026.
These items date from Sept 29 and Oct 1, 2026 for the studies, and July 29, 2026 for the latest recorded action in the FTC case. You can read the full trial and docket records for each of these items on glp1laws.com.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.